Brian Skorney

Baird Analyst Says 'Don't 'Give Up' Yet On Gilead's Remdesivir
Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment
Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia
Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment
Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia
Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade
Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes

Brian Skorney Recent News

Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar
Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises
Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock
Analyst: Regeneron Is Undervalued By The Street
Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings
Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure
Celgene's Pipeline In Question After GED Failure
Analyst Says Axovant's Bull Case Is Effectively Over
FDA Letter On Intercept Pharma Doesn't Include Black Box Warning Label...Yet
Expectations For Regeneron No Longer Realistic; Analyst Downgrades
Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva
The Street Is Misreading Sarepta's Guidance
Gilead's 2017 Guidance Sank Shares To A New Bottom
Theravance Biopharma's Valuation Has Gotten A Little Carried Away
Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations
Patent Trial And Appeal Board Hands Sarepta Another Big Win
Drug Trial Extension By FDA Doesn't Change Baird's Outlook On Sarepta
Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So
Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term
Baird And Piper Jaffray Love Vertex: Here's Why
All-Star Analysts Discuss GoPro, Apple & Gilead Before They Make Headlines
Baird Comments On Achillion's Bullish Share Action
VRTX Well Positioned To Capture Initial Paradigm Shift In Hep C Therapy